A770041, which was developed as a targeted Lck inhibitor, targets a downstream effector of the integrin signaling pathway and thus can be more specific with respect to the cytoskeletal changes that control glioma cell migration than Cilengitide. Here, LCK is linked to central nervous system cancer.